Philogen SpA (DE:78Q) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Philogen S.p.A. is conducting a Phase 2 clinical study titled ‘A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Cutaneous Squamous Cell Carcinoma Patients Progressing on or Intolerant to Systemic Treatment.’ The study aims to evaluate the activity, safety, and efficacy of L19IL2/L19TNF in patients with locally advanced cutaneous squamous cell carcinoma who have not responded to or cannot tolerate immune checkpoint inhibitors.
The intervention involves the experimental use of the drug L19IL2/L19TNF, administered intratumorally to target lesions. This treatment is designed to be given once weekly for up to four weeks, with the possibility of an additional four-week course based on patient response.
The study is designed as an open-label, single-arm, multicenter trial with no masking, focusing on treatment as its primary purpose. Patients will be followed for up to 160 weeks to monitor outcomes.
Key dates for the study include a start date of November 7, 2025, and a last update on December 10, 2025. These dates are crucial for tracking the study’s progress and any updates in its status.
For investors, this study could influence Philogen’s stock performance, as successful results may enhance the company’s market position in the oncology sector. Competitors in the field of cancer treatment may also be impacted by these developments.
The study is currently not yet recruiting, with further details available on the ClinicalTrials portal.
To learn more about DE:78Q’s potential, visit the Philogen SpA drug pipeline page.